 |
|
Psoriasis From the Patient's Point of View
Arch Dermatol. 2001;137:352-353.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
THE ANALYSIS of the views of over 17 000 patients with psoriasis is a staggering task. Krueger et al,1 as reported in this issue of the ARCHIVES, received a 44% return from all of the members of the National Psoriasis Foundation, who were surveyed to assess the realities of living with psoriasis and having it treated. This study provides very powerful information about a disease of central importance to all dermatologists. There are important messages for us about our attitudes as practicing dermatologists, as 32% of the patients with severe psoriasis surveyed said that treatment was not aggressive enough. Our caution in embarking on systemic therapy, with all its attendant risks and requirements for patient explanation, monitoring, and expense, is understandable. The results of the survey, however, raise a nagging and often unvoiced concern. Is it easier for us to play down the benefits and play up the risks of systemic . . . [Full Text of this Article]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
The Impact of Psoriasis on Quality of Life: Results of a 1998 National Psoriasis Foundation Patient-Membership Survey
Gerald Krueger, John Koo, Mark Lebwohl, Alan Menter, Robert S. Stern, and Tara Rolstad
Arch Dermatol. 2001;137(3):280-284.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Efficacy and Safety Observed During 24 Weeks of Efalizumab Therapy in Patients With Moderate to Severe Plaque Psoriasis
Menter et al.
Arch Dermatol 2005;141:31-38.
ABSTRACT
| FULL TEXT
|
